After three phase 1 trials of IDH inhibitors in IDH-mutant glioma and a perioperative head-to-head comparison, a double-blind, placebo-controlled phase 3 trial was designed to assess efficacy of vorasidenib in low-grade tumors. This evidence concerns the gene IDH1 and central nervous system cancer.